SO-18: Reinforcing clinical outcomes with patient-reported QoL outcomes in patients with mCRC receiving FTD/TPI: pooled analysis of PRECONNECT and TALLISUR studies - Lucjan Wyrwicz, et al
SO-19: Biomarker analysis using plasma angiogenesis factors in the TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab as second-line treatment for metastatic colorectal cancer - Hiroya Taniguchi, et al
SO-20: Stanniocalcin 1 (STC1) in patients with refractory colorectal cancer (CRC) treated with regorafenib: An exploratory analysis of the CORRECT trial - Christophe Borg, et al
SO-21: Optimal maintenance treatment strategy following an anti-EGFR-based first-line induction therapy in patients with RAS wild type metastatic colorectal cancer: an individual patient data pooled analysis of clinical trials - Alessandra Raimondi, et al
